DOI: 10.12890/2026_006560

Unmasking VEXAS syndrome: a rare case with crescentic glomerulonephritis

Authors

  • Tattvam Shah Dinbandhu Charitable Trust Hospital, Gujarat, India

shahtattvam24@gmail.com

Keywords

VEXAS syndrome, autoimmune, pancytopenia, haemato-inflammatory

Abstract

Introduction: VEXAS (vacuoles, E1-enzyme, X-linked, autoinflammation, and somatic) syndrome is a newly recognized autoinflammatory hematologic condition due to mutations in the UBA1 gene. This case demonstrates its clinical variability, such as neutrophilic dermatosis, pulmonary disease, and a rare presentation with acute kidney injury and glomerulonephritis.
Case description: A 77-year-old man with a history of benign prostatic hyperplasia, osteoarthritis, and patent foramen ovale presented with fatigue, night sweats, weight loss, and recurrent rashes, diagnosed as neutrophilic dermatosis. Laboratory results were pancytopenia and nephrotic-range proteinuria, and imaging revealed mediastinal lymphadenopathy and pulmonary ground-glass opacities. Bone marrow biopsy showed hypercellularity with vacuolization of myeloid and erythroid precursors. Renal biopsy revealed proliferative necrotizing and crescentic glomerulonephritis. Genetic analysis confirmed the UBA1 p.Met41Val mutation, diagnosing VEXAS syndrome. Treatment with corticosteroids, tocilizumab, and mycophenolate mofetil initially improved the symptoms, but steroid dependence continued. Severe pancytopenia necessitated changing to azacitidine after a year, and the patient was assessed for stem cell transplantation. His course was additionally complicated by neutrophilic pulmonary alveolitis.
Conclusion: VEXAS syndrome presents with recurring fever, arthritis, pulmonary and cutaneous involvement, and cytopenias. Diagnosis needs to be entertained in the context of cryptic cytopenias and antineutrophil cytoplasmic antibodies (ANCA)-negative vasculitis. Renal involvement is atypical, especially in ANCA negative cases. Treatment continues to remain difficult, with the initial first-line therapy as high-dose glucocorticoids, with the alternative options being Janus kinase inhibitors, interleukin-6 inhibitors, and stem cell transplant. The case highlights the value of identifying both characteristic and atypical presentations of VEXAS syndrome. Prompt genetic testing is essential in diagnosis, and management entails a multidisciplinary strategy.

View the entire article

Downloads

References

  1. Sullivan MM, Mead-Harvey C, Sartori-Valinotti JC, Kalantari K, Kusne YN, Patnaik MM, et al. Vasculitis associated with VEXAS syndrome. Rheumatology (Oxford) 2025;64:3889–3894. doi: 10.1093/rheumatology/keae550
  2. Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E, et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients. Br J Dermatol 2022;186:564–574. doi: 10.1111/bjd.20805
  3. Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med 2020;383:2628–2638. doi: 10.1056/NEJMoa2026834
  4. Ferrada MA, Savic S, Cardona DO, Collins JC, Alessi H, Gutierrez-Rodrigues F, et al. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood 2022;140:1496–1506. doi: 10.1182/blood.2022016985
  5. Mathurin M, Hirsch P, Jachiet V, Hadjadj J, Le Guenno G, Heiblig M, et al. A clinicopathological description of kidney features in VEXAS syndrome. Kidney Int Rep 2025;10:260–264. doi: 10.1016/j.ekir.2024.10.026
  6. Murillo-Chavez F, Antiochos B. VEXAS syndrome as a mimicker of ANCA-associated vasculitis. Rheumatol Adv Pract 2024;8:rkae116. doi: 10.1093/rap/rkae116
  7. Bourbon E, Heiblig M, Gerfaud Valentin M, Barba T, Durel CA, Lega JC, et al. Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood 2021;137:3682–3684. doi: 10.1182/blood.2020010177
  8. Hadjadj J, Nguyen Y, Mouloudj D, Bourguiba R, Heiblig M, Aloui H, et al. Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX. Ann Rheum Dis 2024;83:1358–1367. doi: 10.1136/ard-2024-225640
  9. Gurnari C, Koster L, Baaij L, Heiblig M, Yakoub-Agha I, Collin M, et al. Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT. Blood Adv 2024;8:1444–1448. doi: 10.1182/bloodadvances.2023012478

Published

2026-04-07

Issue

Vol. 13 No. 4 (2026)

Categories

How to Cite

1.
Shah T. Unmasking VEXAS syndrome: a rare case with crescentic glomerulonephritis. EJCRIM [Internet]. 2026 Apr. 7 [cited 2026 Nov. 3];13(4). Available from: https://ejcrim.com/index.php/ejcrim/article/view/6560